China adds 30 drugs to its "urgently needed" list

Philip Katz, Xin Tao
Hogan Lovells
Contact
LinkedIn
Facebook
X
Send
Embed

Faster review periods and waiver of requirement for Chinese clinical trials are intended to encourage marketing applications -

On 28 March China's National Medical Products Administration (NMPA) published a list of an additional 30 drugs that are "urgently needed" in China, and for which NMPA seeks to encourage the submission of marketing applications.

Please see full publication below for more information.

View PDF
Download PDF [339KB]
Email
Report

LOADING PDF: If there are any problems, click here to download the file.
Send Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Hogan Lovells

Written by:

Hogan Lovells
Hogan Lovells
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Hogan Lovells on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide